Merck KGaA: MS drug to be covered in Canada
(CercleFinance.com) - EMD Serono, the biopharmaceutical unit of Germany's Merck, has reached an agreement with Canadian regulators on the terms of public reimbursement for its multiple sclerosis pill Mavenclad.
Serono has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), signing a letter of intent, which will facilitate work with authorities to implement public funding of Mavenclad for eligible patients.
Mavenclad is currently reimbursed by most private drug insurance plans, as Canada has one of the highest rates of multiple sclerosis in the world.
Mavenclad was approved by Health Canada in 2017 as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS).
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Serono has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), signing a letter of intent, which will facilitate work with authorities to implement public funding of Mavenclad for eligible patients.
Mavenclad is currently reimbursed by most private drug insurance plans, as Canada has one of the highest rates of multiple sclerosis in the world.
Mavenclad was approved by Health Canada in 2017 as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS).
Copyright (c) 2019 CercleFinance.com. All rights reserved.